Morphic Medical appoints new CEO as it prepares for European expansion

Published 05/08/2025, 07:12
Morphic Medical appoints new CEO as it prepares for European expansion

LONDON - Morphic Medical (TASE:BLWV) Inc. (MMI), a medical device company focused on minimally invasive treatments for obesity and cardiometabolic disorders, has appointed Mike Gutteridge as its new Chief Executive Officer, according to a Tuesday statement from Crystal Amber Fund Limited, which owns 96.7% of MMI.

Gutteridge, who previously served as MMI’s Commercial Director, succeeds Joe Virgilio, who stepped down after five years with the company. The leadership change comes shortly after MMI received CE Mark certification for its RESET® therapy last month.

The CE Mark designation certifies that the RESET® therapy has met European Commission requirements for safety, health, and environmental protection. According to the company statement, this makes it the first endoscopic, non-surgical treatment approved for both obesity and Type 2 diabetes in Europe, potentially providing access to treatment for an estimated 93 million European patients living with these conditions.

"I am honoured to become Chief Executive," Gutteridge said in the statement. "With over thirty years in the MedTech sector spanning clinical innovation, commercial strategy, market development and reimbursement, I am energised by the opportunity to lead Morphic into its next phase."

Christopher Waldron, Chairman of Crystal Amber Fund, thanked the outgoing CEO for "delivering CE Mark and for all his efforts and commitment to innovation and patient care," adding that the board is "excited that Mike, who brings a successful track record of international commercialisation, will be leading MMI as it enters a new and exciting stage of growth."

The announcement was made in a press release from Crystal Amber Fund Limited.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.